+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.

Age: 18Years - 50YearsFEMALEPhase 3
120 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
C

Actively Recruiting

Researchers are evaluating empasiprubart compared to intravenous immunoglobulin IVIg for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP. This Phase 3 study aims to assess the effectiveness and safety of these treatments in people who have responded to IVIg in the past and currently have active disease with residual disability. The study has two parts. In Part A, lasting 24 weeks, participants receive either empasiprubart plus a placebo resembling IVIg or IVIg plus a placebo resembling empasiprubart. After Part A, all participants enter Part B, a 96-week period where they receive empasiprubart without IVIg. Some participants also receive a placebo to maintain the blinding during Part A. Participants will be monitored through various assessments including changes in disability scores, grip strength, and quality of life measures at baseline and throughout the study periods. Researchers will also track adverse events, antibody formation against empasiprubart, and serum drug levels. Total participation spans approximately 120 weeks, including both study parts and ongoing evaluations.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are evaluating empasiprubart for adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a condition causing nerve inflammation and muscle weakness. This Phase 3 randomized, double-blinded, placebo-controlled study aims to demonstrate the efficacy and safety of empasiprubart in treating CIDP. The study is sponsored by argenx and includes adults diagnosed with typical or variant forms of CIDP who have active disease and residual disability. Participants are randomly assigned in part A to receive either empasiprubart or a placebo by intravenous infusion for 24 weeks 6 months. After part A, all participants enter part B, where everyone receives empasiprubart for 96 weeks 24 months. Participants who received empasiprubart in part A will receive a placebo infusion once during part B to maintain blinding. Throughout the study, participants will undergo regular assessments including the adjusted Inflammatory Neuropathy Cause and Treatment aINCAT score, grip strength measurements, muscle strength evaluations, and quality of life questionnaires. Researchers will monitor changes from baseline in motor function, disability, and symptom severity up to 24 weeks in part A and continue evaluations through part B. Safety measures include tracking adverse events and immune responses. The total participation duration can last up to 120 weeks approximately 30 months.

Age: 18Years +All GendersPhase 3
89 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
A

Actively Recruiting

This research aims to study pediatric participants under 12 years old with influenza to evaluate the prevalence of specific amino acid changes that might affect the viruss susceptibility to baloxavir marboxil. The study includes two parts Part A focuses on surveillance of resistance-associated substitutions before and after treatment, while Part B examines the transmission of influenza from treated children to their household contacts. Enrollment for Part B has stopped as per the latest protocol version. Participants in Part A receive a single oral dose of baloxavir marboxil on the first day, with the dose based on their body weight and age. Household contacts of these participants may be enrolled in Part B but do not receive treatment. The study monitors viral changes and resistance by collecting samples on days 1, 4, 6, and 10, with further assessments up to day 29. The study is open-label and conducted across multiple centers. During the study, participants will be assessed for resistance-associated virus mutations and changes in viral load using laboratory tests including RT-PCR. Household contacts are monitored for influenza transmission and symptoms. Safety is tracked by reporting adverse events during the follow-up period. This trial is expected to continue until mid-2027, with participants involved for up to 29 days after dosing for primary evaluations and extended monitoring of virus resistance and transmission.

Age: 3Weeks - 11YearsAll GendersPhase 3
51 locations
R

Actively Recruiting

Researchers are conducting a Phase 2 study to find the appropriate dose of CK-4021586 in adults aged 40 to 85 with symptomatic heart failure with preserved ejection fraction HFpEF. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of this drug in people with this condition, which involves heart failure while maintaining a normal ejection fraction. The trial is randomized, double-blind, and placebo-controlled to provide reliable results. Participants may receive different daily doses of CK-4021586 150 mg, 300 mg, 450 mg, or 600 mg for up to 12 weeks, with dosing guided by echocardiography assessments. There are several study groups, including placebo groups, to compare the effects of the drug. The dose levels are organized in cohorts, with participants assigned randomly to receive either the drug or placebo over the 12-week treatment period. During the study, participants will undergo regular evaluations including echocardiography to monitor left ventricular ejection fraction LVEF and blood tests for NT-proBNP levels, a marker of heart failure. The researchers will assess drug safety by tracking adverse events and early discontinuation rates. Blood samples will also be taken to measure drug concentrations and how these relate to changes in heart function. Total participation lasts for 12 weeks, during which participants have scheduled visits for monitoring and assessments.

Age: 40Years - 85YearsAll GendersPhase 2
26 locations
R

Actively Recruiting

Researchers are evaluating VIA Disc NP, a non-surgical treatment designed to supplement the nucleus pulposus tissue in degenerated intervertebral discs. This randomized, sham-controlled, multi-center, double-blind clinical trial includes participants with lumbar discogenic pain related to degenerative disc disease DDD. The study aims to assess the safety and effectiveness of this treatment for managing moderate to severe disc-related back pain. Participants will receive one VIA Disc NP treatment injected into each affected disc level, with up to two levels treated per person. After an initial open-label roll-in period, participants are randomized in a 21 ratio to receive either the VIA Disc NP injection or a sham procedure that mimics the treatment without injecting any material. Participants in the sham group who still have symptoms after 12 months may cross over to receive the VIA Disc NP treatment and continue follow-up for another 12 months. During the study, participants will be closely monitored through scheduled visits to evaluate pain reduction using the Visual Analog Scale VAS and to record any treatment-related adverse events over 12 months. The main outcomes include the proportion of participants achieving meaningful pain improvement and the frequency of adverse events related to the treatment. Follow-up assessments and monitoring will continue throughout the study duration, which extends up to the study completion date in October 2028.

Age: 22Years - 85YearsAll GendersPhase Not Applicable
19 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of Novosis Putty compared to standard bone graft care in patients undergoing transforaminal lumbar interbody fusion TLIF surgery for lumbar degenerative disc disease. This pivotal, randomized, prospective, multi-center study focuses on adults aged 21 to 80 who have symptomatic lumbar degeneration confirmed by imaging and have not improved after at least six months of conservative treatment. Participants are randomly assigned to receive either TLIF surgery using Novosis Putty or the standard bone graft method. Both groups undergo single-level TLIF surgery, and treatments are administered in a double-blind fashion. The study includes a long-term follow-up period to assess various outcomes up to 60 months after surgery. During the trial, participants are assessed at multiple time points for overall success, fusion success, disability index scores ODI, pain levels VAS, quality of life SF-12, treatment satisfaction, and intraoperative variables. Follow-up visits occur at 6 weeks, 3, 6, 12, 24, 36, 48, and 60 months post-surgery. The primary outcome is overall success measured 24 months after surgery. Safety and efficacy are closely monitored throughout the study, which may last up to nearly six years.

Age: 21Years - 80YearsAll GendersPhase 3
10 locations

1-10 of 18

1